Whole Gene, Whole Haplotype & Whole Genome Sequencing

Revolution in Genetics

As a pioneer in HLA sequence based typing, we have provided millions of cost effective HLA SBT for donor registries, pharmacogenomics, donor centers, cord blood typing, transplant centers, and HLA laboratories.

Histogenetics is applying the new sequencing technologies to study all living species.

Histogenetics’ innovative work led to SBT becoming the standard for HLA typing, making other methods obsolete for high-resolution HLA typing in donor recruitment and patient matching for blood stem cell transplantation since 2006.

With our proprietary process we provide a full suite of tissue-typing and Genomic services with the highest level of quality assurance and accelerated turnaround times.

By introducing SMRT sequencing for routine HLA testing for whole gene Class I and Long Range Class II, Histogenetics set the new Gold Standard.

Currently Histogenetics is applying the advances in genomic technologies such as PacBio Sequel and BioNanao Saphyr platforms for the analysis of Whole genome by Sequencing and Optical Mapping, respectively. This will enable us to determine the complex genetic regions and structural variations that could be the basis for health and diseases. This new information will lay the foundation for Precision Medicine.



Dr. Soo Young Yang,


Dr. Yang pioneered development of biochemical and molecular typing methods for HLA at the Biochemical and Molecular Immunogenetics Laboratory at Memorial Sloan-Kettering Cancer Center.With over 40 years of extensive research and experience in HLA genetics, Dr. Yang has created invaluable reagents and informatics for biochemical and molecular typing of HLA that have contributed significantly to the field of human immunogenetics. This internationally recognized expertise forms the foundation of HistoGenetics' advanced technologies and services.


Dr. Nezih Cereb,


Dr. Cereb has been a long time associate of Dr. Yang, with whom he has played a key role in elucidating the HLA-Class 1 intron sequences that made HLA class 1 DNA typing feasible. Dr. Cereb is an expert in introducing, integrating and implementing diverse technologies for HLA typing and has made high volume, high throughput and high resolution HLA-SBT a reality. His proven abilities stem from a diverse background in clinical medicine, particularly bone marrow transplantation and basic and applied immunogenetics research.



ASHI Member Number CLIA Certificate Number
03-1-NY-26-2 33D0985173

The latest robotics and bioinformatics technology allow us to emphasize extremely high quality and fast turnaround times for results at a very competitive price.


We provide high-quality, cost-effective typing for:

HLA -A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1 and -DPB1

HLA -E, -G


KIR typing by NGS

Molecular ABO Rh typing

CCR5 typing

CMV typing

T Cell Receptor (TCR) Repertoire analysis by NGS

Hemoglobin Beta Gene

Monitoring engraftment and parentage testing

Whole Genome sequencing on PacBio Sequel platform

Whole genome optical mapping on BioNano Saphyr platform

Reporting turnaround time (Working Days)

3 days for ultra urgent clinical samples

5 days for urgent clinical samples

8 days for standard clinical samples

21 days for registry/research typing samples

(TAT can be tailored for client requirements)

Levels of Resolution

Class I: Antigen Recognition Site (ARS) Typing for exon 2 and 3 in phase
Class II: ARS Typing for exon 2

Class I: Exon 2, 3 and 4 typing
Class II: Exon 2 and 3 typing

Class I: Exon 2, 3 and 4 typing, and ruling out CWD null alleles
Class II: Exon 2 and 3 typing

Class I: Exons 1-8 typing
Class II: Exons 2-6 typing

Class I: All exons and introns typing
Class II: Exons 2-6 and introns 2-5 typing

Levels of HLA High Resolution Typing Under NGS Microscope

Select your desired resolution below to create a typing diagram
  • 1x
  • 2x
  • 3x
  • 4x
  • 8x
  • reset
  • Class I

  • Antigen Recognition Site (ARS) Typing for exon 2 and 3 in phase
  • Exon 2, 3 and 4 typing
  • Exon 2, 3 and 4 typing, and ruling out CWD null alleles
  • Exons 1-8 typing
  • All exons and introns typing
  • exon 1
  • exon 2
  • exon 3
  • exon 4
  • exon 5
  • exon 6
  • exon 7
  • exon 8
  • exon 1
  • exon 2
  • exon 3
  • exon 4
  • exon 5
  • exon 6
  • exon 7
  • exon 8
  • Introns
  • CWD Null
  • ARS Typing
  • ARS Typing
  • CWD Null
  • CWD Null
  • CWD Null
  • Class II

  • Antigen Recognition Site (ARS) Typing for exon 2
  • Exon 2 and 3 typing
  • Exon 2 and 3 typing
  • Exons 2-6 typing
  • Exons 2-6 and introns 2-5 typing
  • exon 1
  • exon 2
  • exon 3
  • exon 4
  • exon 5
  • exon 6
  • exon 1
  • exon 2
  • exon 3
  • exon 4
  • exon 5
  • exon 6

Our main sequencing platforms are Next Generation Sequencing (NGS) technology using
Illumina MiSeq
Illumina HiSeq

and Third generation sequencing technology with

Pacific Biosciences RS II and

Pacific Biosciences Sequel platforms.

We have a large fleet of HiSeq 2500s and MiSeqs and maintain our capillary sequencing of 3730xl (Sanger sequencing) platform for ultra-urgent requests.

We use SMRT sequencing for routine HLA testing for whole gene Class I and Long-Range Class II.

We resolve ambiguities that are not resolved using the Illumina approach and further characterize novel alleles using SMRT sequencing.

With around-the-clock operations and built-in redundancies, we can meet tight deadlines for typing requests without sacrificing accuracy. We process all samples and typing requests with the sophisticated automated instrumentation and bioinformatics tools; accuracy of allele-level typing is further assured by built-in redundancies.


HLA molecules serve as biological ID for humans that discriminates self from external and internal foreign bodies. Learn more about HLA here: Read more

External foreign bodies are infectious agents (viruses, bacteria, fungi, parasites), food, foreign tissue, drugs and etc. Internal factors are tissue modification due to infections, cancer and physical trauma (heat, cold etc). Learn more here: Read more

In the 1950s it was shown that organ and tissue transplantation could offer a cure for numerous illnesses. But the success of these procedures depends to the matching degree between the patient and their donor for HLA.

The regions of HLA proteins that interact with T-cell receptors polypeptides (proteins) are extremely variable from individual to individual (polymorphic), and they are called Antigen Recognition Sites (ARS). The polymorphism is conferred by DNA sequences that encode those polypeptides (proteins). In Class I molecules (HLA-A, -B, -C) exon 2 and 3 of Class I genes encodes for those polypeptides and they are called ARS exons. In Class II molecules (HLA-DRB1, -DQB1 and DPB1) exon 2 of class II genes encodes the ARS regions.

Therefore in HLA testing we primarily sequence those exons and predict the protein sequences (1x High Resolution). DNA sequences that result in identical protein sequences for ARS regions are considered a match.

Some clinicians would like to test to see if it is possible to match for alpha-3 domain of HLA proteins. Exon 4 and Exon 3 of Class I and Class II genes encode alpha-3 polypeptides, respectively (2x high resolution). If alpha-3 regions are not matching but ARS regions match, if that donor is the best available donor otherwise, he/she could be selected for blood stem cell donation.

Some irregularities in DNA sequences may result in no expression or expression of totally non-functional protein. Those irregularities could be missing base(s) (deletions), have extra base(s) (insertions), or have base substitutions that result in premature termination of HLA protein synthesis (early stop codons). In certain cases those irregularities could happen in regions of the genes that are outside of the ARS regions. Therefore by just testing for ARS DNA sequences, one may miss those null alleles. This could result in calling a mismatch typing as a match and could affect the success of the transplant outcome.

Those null alleles that have seen at least five times in different ethnic populations are tested in donors and patients. We call this extra test as testing for CWD null alleles. (3x High resolution).

Now with advances of Next Generation Sequencing (NGS) technologies, especially of Illumina and Pacific Biosciences we can sequence all exons of class I (7 Exons HLA-B, 8 exons HLA-A and –C) and Class II ( 4x High Resolution). When requested we can also provide the sequences of non-coding region between the exons, introns, along with the exon sequences (8x High Resolution).


HistoGenetics provides a suite of tissue-typing services with the highest level of quality assurance and accelerated turnaround times. Our prices are competitive and we can handle any volume.

Please fill in all details and click the Submit button when completed. We will respond to your request as soon as possible. Your information is private and will never be shared with third parties.

send email

Our Location

contact details

300 Executive Blvd
Ossining, New York, USA - 10562

phone: 1-914-762-0300
fax: 1-914-762-4441

[email protected]